Loading…
TruAlt Bioenergy (TRUALT)₹351.20−4.84%Other Agricultural Products
In the Sep 2026 quarter (consolidated), TruAlt Bioenergy reported sales of ₹809 Cr, up 605.9% from Sep 2025, and net profit of ₹34.99 Cr. For the year to Mar 2026, sales were ₹1,721 Cr and net profit ₹97.10 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 196 | 387 | 414 | 903 | 303 | 115 | 710 | 594 | 625 | 809 |
| Expenses | 184 | 370 | 291 | 752 | 261 | 119 | 579 | 465 | 493 | 708 |
| Operating Profit | 13.95 | 16.96 | 125 | 154 | 41.91 | −4.99 | 134 | 129 | 133 | 101 |
| OPM % | 7.0% | 4.5% | 29.9% | 17.0% | 14.0% | −4.0% | 19.0% | 22.0% | 21.0% | 12.0% |
| Other Income | 14.97 | 16.98 | 14.98 | 13.96 | 22.94 | 14.96 | 17.97 | 30.92 | 14.96 | 12.97 |
| Interest | 35.05 | 34.02 | 36.06 | 39.05 | 38.03 | 39.03 | 40.03 | 44.07 | 44.06 | 42.06 |
| Depreciation | 15.96 | 15.96 | 17.94 | 17.94 | 20.94 | 20.93 | 21.94 | 22.94 | 24.93 | 23.94 |
| Profit before tax | −21.95 | −15.97 | 85.79 | 111 | 5.98 | −48.86 | 89.83 | 93.82 | 77.86 | 46.87 |
| Tax % | 0.0% | 15.1% | 13.1% | −1.0% | 18.1% | −23.0% | 23.1% | 27.1% | 24.1% | 26.1% |
| Net Profit | −21.99 | −18.99 | 74.99 | 112 | 5.01 | −38.02 | 69.01 | 69.07 | 59.03 | 34.99 |
| EPS (Rs) | −3.04 | −2.63 | 10.63 | 15.78 | 0.66 | −4.41 | 8.06 | 7.89 | 6.64 | 4.03 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales | 759 | 1,219 | 1,900 | 1,721 | 2,738 |
| Expenses | 656 | 1,033 | 1,597 | 1,436 | 2,245 |
| Operating Profit | 105 | 187 | 308 | 289 | 495 |
| OPM % | 14.0% | 14.9% | 16.0% | 17.0% | 18.1% |
| Other Income | 0.00 | 56.87 | 60.83 | 85.77 | 76.82 |
| Interest | 35.07 | 143 | 144 | 160 | 170 |
| Depreciation | 20.95 | 56.86 | 66.79 | 85.77 | 93.75 |
| Profit before tax | 48.89 | 44.90 | 159 | 130 | 308 |
| Tax % | 28.1% | 29.1% | 8.0% | 25.1% | — |
| Net Profit | 35.01 | 32.01 | 147 | 97.10 | 232 |
| EPS (Rs) | 5.79 | 5.20 | 20.72 | 11.16 | 26.62 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 61.13 | 61.13 | 71.16 | 86.05 |
| Reserves | 180 | 205 | 700 | 1,436 |
| Borrowings | 1,148 | 1,683 | 1,555 | 1,648 |
| Other Liabilities | 463 | 467 | 701 | 603 |
| Total Liabilities | 1,853 | 2,415 | 3,026 | 3,773 |
| Fixed Assets | 1,300 | 1,425 | 1,824 | 2,181 |
| CWIP | 10.02 | 201 | 3.01 | 68.20 |
| Investments | 0.00 | 10.01 | 4.01 | 4.01 |
| Other Assets | 544 | 779 | 1,195 | 1,519 |
| Inventories | 153 | 159 | 210 | 528 |
| Trade receivables | 87.14 | 299 | 339 | 407 |
| Cash & equivalents | 5.01 | 23.03 | 150 | 90.11 |
| Total Assets | 1,853 | 2,415 | 3,026 | 3,773 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | 233 | 35.05 | 342 | −297 |
| Cash from investing activity | −1,153 | −385 | −256 | −414 |
| Cash from financing activity | 920 | 366 | 39.93 | 647 |
| Net cash flow | 4.99 | 18.99 | 126 | −61.92 |
| Capex | 275 | 356 | 259 | 509 |
| Free cash flow | −42.09 | −322 | 82.25 | −807 |
| CFO / OP % | 222.0% | 21.0% | 110.0% | −99.1% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 41 | 89 | 65 | 86 |
| Inventory days | 111 | 71 | 59 | 172 |
| Days payable | 225 | 70 | 139 | 89 |
| Cash conversion cycle | −72 | 92 | −14 | 170 |
| Working capital days | 9 | −129 | −26 | 64 |
| ROCE % | — | 11.1% | 14.1% | 10.0% |
For the Sep 2026 quarter, TruAlt Bioenergy reported sales of ₹809 Cr, up 605.9% year on year and net profit of ₹34.99 Cr. The operating margin was 12.0%.
TruAlt Bioenergy's sales for the year to Mar 2026 were ₹1,721 Cr; over the last twelve months they were ₹2,738 Cr.
Net profit for the year to Mar 2026 was ₹97.10 Cr, and ₹232 Cr over the last twelve months. Earnings per share over the same trailing period were ₹26.62.
TruAlt Bioenergy reported borrowings of ₹1,648 Cr at Mar 2026, against cash and equivalents of ₹90.11 Cr.
Cash from operations was −₹297 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹807 Cr.